New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 17, 2014
09:59 EDTMDCO, NGLS, SDRL, MDP, STKL, R, HBAN, SO, IMO, EPDOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Enterprise Products (EPD) downgraded to Hold from Buy at Jefferies... Huntington Bancshares (HBAN) downgraded to Outperform from Strong Buy at Raymond James... Imperial Oil (IMO) downgraded to Sell from Hold at Desjardins... Meredith (MDP) downgraded to Neutral from Buy at Citigroup... Ryder (R) downgraded to Hold from Buy at Stifel... Seadrill (SDRL) downgraded to Neutral from Buy at BofA/Merrill... Southern Company (SO) downgraded to Sector Perform from Outperform at RBC Capital... SunOpta (STKL) downgraded to Sell from Hold at Desjardins... Targa Resources Partners (NGLS) downgraded to Hold from Buy at Jefferies... The Medicines Co. (MDCO) downgraded to Market Perform from Outperform at Leerink.
News For EPD;HBAN;MDP;IMO;R;SDRL;SO;STKL;NGLS;MDCO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
December 19, 2014
09:10 EDTSDRLSeadrill downgraded to Conviction Sell from Neutral at Goldman
Subscribe for More Information
December 18, 2014
09:27 EDTMDPMeredith initiated with a Neutral at Sidoti
08:58 EDTSTKLSunOpta upgraded to Buy from Hold at Miller Tabak
07:01 EDTMDCOThe Medicines Co., SciClone establish strategic partnership
The Medicines Company (MDCO) and SciClone Pharmaceuticals (SCLN) announced the establishment of a strategic partnership for two cardiovascular products in China. The partnership includes an agreement granting SciClone a license and the exclusive rights in China to promote two products of The Medicines Company: ANGIOMAX for Injection, an anticoagulant indicated in patients undergoing percutaneous coronary intervention with provisional use of glycoprotein IIb/IIIa inhibitor and in patients with, or at risk of, heparin-induced thrombocytopenia and thrombosis syndrome undergoing PCI. A Phase 3 registration trial was completed in China and is currently under review by the China Food and Drug Administration for marketing approval. CLEVIPREX Injectable Emulsion, a third-generation dihydropyridine calcium channel blocker indicated for the reduction of blood pressure when oral therapy is not feasible or desirable. The clinical trial application for China was filed in 2013. Under the terms of the agreement, SciClone will be responsible for all aspects of commercialization, including pre- and post-launch activities, for both products in the China market excluding Hong Kong and Macau. SciClone has also agreed to assist in the China registration process for both products. Financial terms of the agreement, in addition to net sales royalties payable to The Medicines Company, include the following additional payments to The Medicines Company: an upfront payment; a product support services fee; and regulatory/commercial success milestone payments of up to an aggregate of $50.5M.
December 17, 2014
09:33 EDTSOSouthern Company selects First Solar to expand solar development in Georgia
Subscribe for More Information
December 16, 2014
12:26 EDTIMOOn The Fly: Midday Wrap
Subscribe for More Information
11:27 EDTSDRLStocks with call strike movement; SDRL GPRO
Subscribe for More Information
10:57 EDTIMOCanadian energy stocks rise after Talisman acquired by Repsol
Shares of Canadian energy companies are higher this morning after Repsol (REPYY) announced plans to buy Talisman Energy (TLM) for $8 per share in cash. WHAT'S NEW: Canada-based Talisman announced that it has agreed to be acquired by Spain's Repsol in a transaction valued at approximately $13B, including debt. Under the terms of the agreement, Repsol will buy all outstanding common shares of Talisman for $8 per share in cash. Also under the deal, Talisman will pay aggregate cash dividends of 18c per common share prior to closing. The Talisman board is recommending shareholders accept the deal at a special meeting to be held in mid-February 2015. The transaction is expected to close in the second quarter of 2015, Talisman said. Talisman Chairman Chuck Williamson noted that the deal will create "significant and immediate value" for the company's investors. WHAT'S NOTABLE: Repsol first explored a bid for Talisman in July, but talks slowed in late August. Earlier this month, Bloomberg reported the companies revived talks and The Wall Street Journal said "talks moved quickly" from there. Canada Pension Plan Investment Board, which initially considered buying parts of Talisman, was also weighing a bid for the whole company, according to Bloomberg, citing people with knowledge of the matter. ANALYST REACTION: Talisman Energy was downgraded this morning to Market Perform from Outperform at Bernstein. PRICE ACTION: Talisman Energy is up $2.43, or 47.5%, to $7.55 in morning trading and Repsol shares trading in New York are down 1.5% to $19.15. OTHERS TO WATCH: Other Canadian energy companies traded in New York include Encana (ECA), Suncor (SU), Canadian Natural Resource (CNQ) and Imperial Oil (IMO). Of note, Encana this morning announced a 2015 capital program of $2.7B-$2.9B, with about 80% directed to the Montney, Duvernay, Eagle Ford and Permian, its highest margin growth plays. The company expects total cash flow between $2.5B-$2.7B, reflecting the impact of higher margin production and continued cost efficiencies, partially offset by anticipated lower commodity prices. In morning trading, Encana shares rose 9.2% to $12.69, Suncor gained 5.3% to $28.33, Canadian Natural Resource added 4.8% to $28.62 and Imperial Oil advanced 2.5% to $40.88.
December 15, 2014
12:36 EDTEPDEnterprise Products begins open season for expansion of Panola NGL pipeline
Enterprise Products announced the start of a binding open season to seek shipper support for a proposed expansion of the portion of its Panola Pipeline Company natural gas liquids system between Carthage, Texas and Mont Belvieu, Texas. The project is designed to support Haynesville and Cotton Valley oil and gas producers by providing enhanced access to the world’s largest NGL fractionation complex, located in Mont Belvieu. Originating near Carthage in Panola County, the NGL pipeline system extends 181 miles, serving multiple destination points at Mont Belvieu, including facilities owned and operated by Enterprise. Depending on shipper response to the open season, the Panola expansion project would be designed to accommodate approximately 50,000 barrels per day of incremental capacity. Achieving the additional capacity would involve installing additional pipe, pumps and related equipment. The additional capacity is expected to be available in the first quarter of 2016. The open commitment period begins today at noon CST and will close on Friday, January 16, 2015 at 5 p.m. CST.
08:32 EDTSTKLSunOpta signs agreement to sell fiber, starch business for $37.5M
Subscribe for More Information
December 12, 2014
15:02 EDTEPDEnterprise Products says will not develop proposed Bakken-to-Cushing pipeline
Subscribe for More Information
December 11, 2014
08:02 EDTMDCOAlnylam, The Medicines Co. announce initiation of Phase 1 ALN-PCSsc trial
Subscribe for More Information
December 10, 2014
09:36 EDTSDRLActive equity options trading
Subscribe for More Information
09:31 EDTSTKLSunOpta upgraded to Hold from Sell at Desjardins
08:18 EDTSTKLDeutsche Bank to hold a conference
Subscribe for More Information
December 9, 2014
10:23 EDTHBANOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:43 EDTHBANHuntington Bancshares initiated with a Neutral at Guggenheim
December 8, 2014
18:02 EDTSOWashington Gas Energy Systems to evaluate battery storage system in Georgia
Subscribe for More Information
12:25 EDTMDCOAntibiotic makers rise after Merck agrees to buy Cubist
Subscribe for More Information
10:11 EDTMDCOHigh option volume stocks
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use